Filing Flows › Harvard Bioscience (HBIO) › Q1 2026
Harvard Bioscience (HBIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Harvard Bioscience (HBIO) reported revenue of $20.8M for the first quarter 2026 (Q1 2026), -5% from a year earlier and -13% from the quarter before. Operating margin was -5.7%, net loss $3.4M (16.5% of revenue).
Harvard Bioscience, Q1 2026: revenue $20.8M (-5% year over year), operating margin -5.7%, net loss $3.4M, operating cash flow −$662K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.8M | -13% | -5% |
| Operating profit | −$1.2M | -169% | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$662K | — | -122% |
What changed
Revenue was $20.8M in Q1 2026, down 5% year over year and down 13% from the previous quarter. Instruments, Equipment, Software, and Accessories was the largest line at 89% of revenue. Instruments, Equipment, Software, and Accessories lost $1.3M year over year (down 7%), 127% of the total change.
Gross margin was 59.0%, up 3.0 points from Q1 2025. Operating costs exceeded revenue by $1.2M, an operating margin of -5.7%. Operating expenses fell 78% while revenue fell 5%. The quarter ended with a net loss of $3.4M, wider than the previous quarter's $2.8M loss. Net interest and other expense of $2.1M was the main reason.
Operating cash flow was −$662K. Non-cash charges added back $1.3M of depreciation and amortization and $257K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $426K exceeded it, leaving free cash flow of −$1.1M.
Questions
What was Harvard Bioscience's revenue in the first quarter 2026?
Harvard Bioscience (HBIO) reported revenue of $20.8M for the first quarter 2026 (Q1 2026), -5% from a year earlier and -13% from the quarter before.
Was Harvard Bioscience profitable in the first quarter 2026?
Operating loss was $1.2M (-5.7% of revenue) and net loss $3.4M.
Source: Harvard Bioscience 10-Q on SEC EDGAR.